Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28:2022:2813142.
doi: 10.1155/2022/2813142. eCollection 2022.

Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells

Affiliations

Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells

Kuizhong Shan et al. Comput Math Methods Med. .

Abstract

Chemotherapy is a commonly used strategy for advanced lung cancer patients. However, its clinical application is restrained due to its toxicity and drug resistance. Ginsenoside Rg3 (Rg3) has a strong anticancer influence on colon cancer, breast cancer, lung cancer, and other malignant tumors. However, it is still unclear whether Rg3 can cooperate with 5-FU to inhibit the tumor growth and angiogenesis of lung adenocarcinoma (LUAD). This study examined the combined treatment of Rg3 and 5-FU in LUAD. It was revealed that the combined treatment could notably enhance the suppression on proliferative, invasive, and migratory abilities and angiogenesis in LUAD cells A549 and SPC-A-1. On the other hand, we also discovered that Rg3 or 5-FU could suppress the activity of the NF-κB signaling pathway and downregulate VEGFA expression in LUAD cells. Collectively, this study suggested that Rg3 combined chemotherapy may perform a more powerful drug efficiency in LUAD cells.

PubMed Disclaimer

Conflict of interest statement

The authors deny that they have conflicts of interest.

Figures

Figure 1
Figure 1
Combined processing with Rg3 and 5-FU facilitates suppression on the progression of LUAD cells. (a, b) CCK-8 assay measured the viability of A549 and SPC-A-1 cells processed by different concentrations of Rg3 or 5-FU; (c–e) after A549 and SPC-A-1 cells were treated with Rg3 (1 mmol/L), or 5-FU (50 μmol/L) or both, the proliferation, migration, and invasion of A549 and SPC-A-1 cells were detected by colony formation assay (c) and transwell assay (d, e), respectively (∗ denotes P < 0.05).
Figure 2
Figure 2
Combined processing with Rg3 and 5-FU boosts the inhibitory effect on angiogenesis of LUAD cells. After A549 and SPC-A-1 cells were treated with Rg3 (1 mmol/L), or 5-FU (50 μmol/L) or a combination of them, (a) angiogenesis assay showed the angiogenic ability of the cells; (b) western blot expressed the protein expression level of VEGFA in LUAD cells A549 and SPC-A-1 (∗ denotes P < 0.05).
Figure 3
Figure 3
Combined processing with Rg3 and 5-FU inhibits VEGF expression and NF-κB signaling pathway activity in LUAD cells. (a) Protein expression of nuclear protein p-p65 and p65 examined by western blot; (b) protein expression of p-p65, p65, p-IKK, IKK, and VEGFA in cells examined by western blot (∗ denotes P < 0.05).

Similar articles

Cited by

References

    1. Miller K. D., Siegel R. L., Lin C. C., et al. Cancer treatment and survivorship statistics, 2016. CA: a Cancer Journal for Clinicians . 2016;66(4):271–289. doi: 10.3322/caac.21349. - DOI - PubMed
    1. Zaric B., Stojsic V., Tepavac A., et al. Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC) Journal of Thoracic Disease . 2013;5 Suppl 4(Suppl 4):S371–S377. doi: 10.3978/j.issn.2072-1439.2013.05.16. - DOI - PMC - PubMed
    1. Noro R., Miyanaga A., Minegishi Y., et al. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression. Cancer Science . 2010;101(6):1424–1430. doi: 10.1111/j.1349-7006.2010.01559.x. - DOI - PMC - PubMed
    1. Zhao J. G., Ren K. M., Tang J. Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine . 2014;35(12):12305–12315. doi: 10.1007/s13277-014-2543-3. - DOI - PubMed
    1. Sethy C., Kundu C. N. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie . 2021;137, article 111285 doi: 10.1016/j.biopha.2021.111285. - DOI - PubMed

MeSH terms